nodes	percent_of_prediction	percent_of_DWPC	metapath
Lamivudine—ABCC1—Vemurafenib—skin cancer	0.106	0.152	CbGbCtD
Lamivudine—ABCG2—Vismodegib—skin cancer	0.0902	0.128	CbGbCtD
Lamivudine—ABCC3—Fluorouracil—skin cancer	0.0779	0.111	CbGbCtD
Lamivudine—ABCG2—Vemurafenib—skin cancer	0.0713	0.102	CbGbCtD
Lamivudine—ABCC1—Dactinomycin—skin cancer	0.0708	0.101	CbGbCtD
Lamivudine—ABCC4—Fluorouracil—skin cancer	0.0595	0.0848	CbGbCtD
Lamivudine—ABCG2—Dactinomycin—skin cancer	0.0474	0.0675	CbGbCtD
Lamivudine—ABCC1—Docetaxel—skin cancer	0.0365	0.0521	CbGbCtD
Lamivudine—ABCB1—Vismodegib—skin cancer	0.0325	0.0463	CbGbCtD
Lamivudine—ABCG2—Fluorouracil—skin cancer	0.032	0.0456	CbGbCtD
Lamivudine—ABCC2—Docetaxel—skin cancer	0.027	0.0385	CbGbCtD
Lamivudine—ABCG2—Docetaxel—skin cancer	0.0245	0.0348	CbGbCtD
Lamivudine—ABCB1—Dactinomycin—skin cancer	0.0171	0.0243	CbGbCtD
Lamivudine—ABCB1—Docetaxel—skin cancer	0.00882	0.0126	CbGbCtD
Lamivudine—CMPK1—hair follicle—skin cancer	0.00402	0.0464	CbGeAlD
Lamivudine—PGK1—connective tissue—skin cancer	0.00379	0.0437	CbGeAlD
Lamivudine—PGK1—skin of body—skin cancer	0.00342	0.0395	CbGeAlD
Lamivudine—PCYT2—female reproductive system—skin cancer	0.00311	0.0359	CbGeAlD
Lamivudine—PCYT1A—connective tissue—skin cancer	0.003	0.0346	CbGeAlD
Lamivudine—PGK1—Glycolysis—ENO2—skin cancer	0.00291	0.079	CbGpPWpGaD
Lamivudine—NME1—neck—skin cancer	0.0028	0.0323	CbGeAlD
Lamivudine—NME1—Arf6 trafficking events—EXOC2—skin cancer	0.00275	0.0746	CbGpPWpGaD
Lamivudine—PGK1—female reproductive system—skin cancer	0.00267	0.0308	CbGeAlD
Lamivudine—PGK1—Gluconeogenesis—ENO2—skin cancer	0.00261	0.0707	CbGpPWpGaD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.0026	0.0705	CbGpPWpGaD
Lamivudine—PCYT2—head—skin cancer	0.0026	0.03	CbGeAlD
Lamivudine—NME1-NME2—female reproductive system—skin cancer	0.00243	0.0281	CbGeAlD
Lamivudine—NT5C—lymphoid tissue—skin cancer	0.00234	0.027	CbGeAlD
Lamivudine—NT5C—female reproductive system—skin cancer	0.00226	0.026	CbGeAlD
Lamivudine—PGK1—head—skin cancer	0.00223	0.0258	CbGeAlD
Lamivudine—PCYT1A—female reproductive system—skin cancer	0.00212	0.0244	CbGeAlD
Lamivudine—NME1-NME2—head—skin cancer	0.00203	0.0235	CbGeAlD
Lamivudine—NME1—connective tissue—skin cancer	0.00201	0.0232	CbGeAlD
Lamivudine—CMPK1—connective tissue—skin cancer	0.00193	0.0223	CbGeAlD
Lamivudine—NT5C—head—skin cancer	0.00188	0.0217	CbGeAlD
Lamivudine—NME1—skin of body—skin cancer	0.00181	0.0209	CbGeAlD
Lamivudine—PGK1—Glycolysis and Gluconeogenesis—ENO2—skin cancer	0.00181	0.049	CbGpPWpGaD
Lamivudine—NME2—epithelium—skin cancer	0.00179	0.0207	CbGeAlD
Lamivudine—PCYT1A—head—skin cancer	0.00177	0.0204	CbGeAlD
Lamivudine—CMPK1—skin of body—skin cancer	0.00175	0.0202	CbGeAlD
Lamivudine—NME1—lymphoid tissue—skin cancer	0.00147	0.0169	CbGeAlD
Lamivudine—NME1-NME2—lymph node—skin cancer	0.00142	0.0164	CbGeAlD
Lamivudine—NME1—female reproductive system—skin cancer	0.00141	0.0163	CbGeAlD
Lamivudine—CMPK1—lymphoid tissue—skin cancer	0.00141	0.0163	CbGeAlD
Lamivudine—NME2—lymphoid tissue—skin cancer	0.00138	0.016	CbGeAlD
Lamivudine—CMPK1—female reproductive system—skin cancer	0.00136	0.0157	CbGeAlD
Lamivudine—DCK—nipple—skin cancer	0.00136	0.0157	CbGeAlD
Lamivudine—ABCC1—hair follicle—skin cancer	0.00135	0.0156	CbGeAlD
Lamivudine—PGK1—Glucose metabolism—ENO2—skin cancer	0.00134	0.0364	CbGpPWpGaD
Lamivudine—NME2—female reproductive system—skin cancer	0.00133	0.0154	CbGeAlD
Lamivudine—NT5C—lymph node—skin cancer	0.00132	0.0152	CbGeAlD
Lamivudine—SLC22A3—Synaptic Vesicle Pathway—SYP—skin cancer	0.00125	0.0339	CbGpPWpGaD
Lamivudine—NME1—head—skin cancer	0.00118	0.0136	CbGeAlD
Lamivudine—CMPK1—head—skin cancer	0.00114	0.0132	CbGeAlD
Lamivudine—NME2—head—skin cancer	0.00111	0.0129	CbGeAlD
Lamivudine—SLC22A3—nipple—skin cancer	0.00111	0.0128	CbGeAlD
Lamivudine—ABCC3—Fluoropyrimidine Activity—XRCC3—skin cancer	0.00105	0.0285	CbGpPWpGaD
Lamivudine—ABCC4—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000987	0.0268	CbGpPWpGaD
Lamivudine—ABCC1—nipple—skin cancer	0.000915	0.0106	CbGeAlD
Lamivudine—NME1—lymph node—skin cancer	0.000828	0.00955	CbGeAlD
Lamivudine—CMPK1—lymph node—skin cancer	0.000798	0.00921	CbGeAlD
Lamivudine—DCK—mammalian vulva—skin cancer	0.000793	0.00915	CbGeAlD
Lamivudine—SLC22A3—connective tissue—skin cancer	0.000785	0.00906	CbGeAlD
Lamivudine—NME2—lymph node—skin cancer	0.00078	0.009	CbGeAlD
Lamivudine—PGK1—HIF-1-alpha transcription factor network—TERT—skin cancer	0.000776	0.021	CbGpPWpGaD
Lamivudine—ABCG2—Fluoropyrimidine Activity—XRCC3—skin cancer	0.000724	0.0196	CbGpPWpGaD
Lamivudine—DCK—lymphoid tissue—skin cancer	0.000704	0.00813	CbGeAlD
Lamivudine—PGK1—Carbohydrate metabolism—CSPG4—skin cancer	0.000702	0.019	CbGpPWpGaD
Lamivudine—DCK—female reproductive system—skin cancer	0.000679	0.00784	CbGeAlD
Lamivudine—ABCC3—female reproductive system—skin cancer	0.00065	0.0075	CbGeAlD
Lamivudine—SLC22A3—mammalian vulva—skin cancer	0.000646	0.00746	CbGeAlD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—TERT—skin cancer	0.000571	0.0155	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000569	0.0154	CbGpPWpGaD
Lamivudine—DCK—head—skin cancer	0.000567	0.00655	CbGeAlD
Lamivudine—SLC22A3—female reproductive system—skin cancer	0.000553	0.00639	CbGeAlD
Lamivudine—ABCC3—head—skin cancer	0.000543	0.00627	CbGeAlD
Lamivudine—ABCC4—female reproductive system—skin cancer	0.000537	0.00619	CbGeAlD
Lamivudine—ABCC1—mammalian vulva—skin cancer	0.000534	0.00617	CbGeAlD
Lamivudine—ABCC2—female reproductive system—skin cancer	0.000519	0.006	CbGeAlD
Lamivudine—ABCB1—blood vessel—skin cancer	0.000517	0.00596	CbGeAlD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—CDK4—skin cancer	0.000511	0.0139	CbGpPWpGaD
Lamivudine—SLC22A1—head—skin cancer	0.000484	0.00558	CbGeAlD
Lamivudine—PGK1—Carbohydrate metabolism—ENO2—skin cancer	0.000477	0.0129	CbGpPWpGaD
Lamivudine—SLC22A3—head—skin cancer	0.000462	0.00534	CbGeAlD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.00046	0.0125	CbGpPWpGaD
Lamivudine—ABCC4—head—skin cancer	0.000448	0.00518	CbGeAlD
Lamivudine—ABCG2—mammalian vulva—skin cancer	0.000442	0.00511	CbGeAlD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—TERT—skin cancer	0.000433	0.0117	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000431	0.0117	CbGpPWpGaD
Lamivudine—DCK—lymph node—skin cancer	0.000397	0.00459	CbGeAlD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	0.000392	0.0106	CbGpPWpGaD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—CDK4—skin cancer	0.000387	0.0105	CbGpPWpGaD
Lamivudine—ABCC3—lymph node—skin cancer	0.00038	0.00439	CbGeAlD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	0.000372	0.0101	CbGpPWpGaD
Lamivudine—ABCC3—Fluoropyrimidine Activity—ERCC2—skin cancer	0.00037	0.01	CbGpPWpGaD
Lamivudine—ABCC4—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000347	0.00942	CbGpPWpGaD
Lamivudine—SLC22A3—lymph node—skin cancer	0.000324	0.00374	CbGeAlD
Lamivudine—ABCC4—lymph node—skin cancer	0.000314	0.00362	CbGeAlD
Lamivudine—ABCC2—lymph node—skin cancer	0.000304	0.00351	CbGeAlD
Lamivudine—Migraine—Docetaxel—skin cancer	0.000285	0.00163	CcSEcCtD
Lamivudine—Erythema multiforme—Temozolomide—skin cancer	0.000285	0.00163	CcSEcCtD
Lamivudine—Urticaria—Imiquimod—skin cancer	0.000284	0.00163	CcSEcCtD
Lamivudine—Body temperature increased—Imiquimod—skin cancer	0.000283	0.00162	CcSEcCtD
Lamivudine—Abdominal pain—Imiquimod—skin cancer	0.000283	0.00162	CcSEcCtD
Lamivudine—Malaise—Bleomycin—skin cancer	0.000281	0.00161	CcSEcCtD
Lamivudine—Leukopenia—Bleomycin—skin cancer	0.000279	0.00159	CcSEcCtD
Lamivudine—Rhinitis—Fluorouracil—skin cancer	0.000278	0.00159	CcSEcCtD
Lamivudine—Dizziness—Vemurafenib—skin cancer	0.000277	0.00159	CcSEcCtD
Lamivudine—Hypoaesthesia—Fluorouracil—skin cancer	0.000276	0.00158	CcSEcCtD
Lamivudine—Pharyngitis—Fluorouracil—skin cancer	0.000276	0.00158	CcSEcCtD
Lamivudine—Immune system disorder—Temozolomide—skin cancer	0.000272	0.00156	CcSEcCtD
Lamivudine—Mediastinal disorder—Temozolomide—skin cancer	0.000272	0.00156	CcSEcCtD
Lamivudine—Cough—Bleomycin—skin cancer	0.000272	0.00155	CcSEcCtD
Lamivudine—Chills—Temozolomide—skin cancer	0.000271	0.00155	CcSEcCtD
Lamivudine—ABCC1—S1P1 pathway—PTGS2—skin cancer	0.00027	0.00732	CbGpPWpGaD
Lamivudine—Dehydration—Docetaxel—skin cancer	0.00027	0.00154	CcSEcCtD
Lamivudine—Ill-defined disorder—Dactinomycin—skin cancer	0.000269	0.00154	CcSEcCtD
Lamivudine—Anaemia—Dactinomycin—skin cancer	0.000268	0.00154	CcSEcCtD
Lamivudine—ABCC1—lymph node—skin cancer	0.000268	0.00309	CbGeAlD
Lamivudine—Liver function test abnormal—Docetaxel—skin cancer	0.000268	0.00153	CcSEcCtD
Lamivudine—Vomiting—Vemurafenib—skin cancer	0.000266	0.00153	CcSEcCtD
Lamivudine—Alopecia—Temozolomide—skin cancer	0.000266	0.00153	CcSEcCtD
Lamivudine—Myalgia—Bleomycin—skin cancer	0.000265	0.00152	CcSEcCtD
Lamivudine—Chest pain—Bleomycin—skin cancer	0.000265	0.00152	CcSEcCtD
Lamivudine—Abdominal pain upper—Docetaxel—skin cancer	0.000265	0.00152	CcSEcCtD
Lamivudine—Rash—Vemurafenib—skin cancer	0.000264	0.00151	CcSEcCtD
Lamivudine—Dermatitis—Vemurafenib—skin cancer	0.000264	0.00151	CcSEcCtD
Lamivudine—Hypersensitivity—Imiquimod—skin cancer	0.000263	0.00151	CcSEcCtD
Lamivudine—Headache—Vemurafenib—skin cancer	0.000263	0.0015	CcSEcCtD
Lamivudine—Malnutrition—Temozolomide—skin cancer	0.000262	0.0015	CcSEcCtD
Lamivudine—Erythema—Temozolomide—skin cancer	0.000262	0.0015	CcSEcCtD
Lamivudine—Discomfort—Bleomycin—skin cancer	0.000262	0.0015	CcSEcCtD
Lamivudine—Malaise—Dactinomycin—skin cancer	0.000262	0.0015	CcSEcCtD
Lamivudine—Cramp muscle—Docetaxel—skin cancer	0.000261	0.00149	CcSEcCtD
Lamivudine—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000261	0.00149	CcSEcCtD
Lamivudine—Leukopenia—Dactinomycin—skin cancer	0.00026	0.00149	CcSEcCtD
Lamivudine—Nasopharyngitis—Docetaxel—skin cancer	0.000259	0.00148	CcSEcCtD
Lamivudine—Dysgeusia—Temozolomide—skin cancer	0.000257	0.00147	CcSEcCtD
Lamivudine—Asthenia—Imiquimod—skin cancer	0.000256	0.00147	CcSEcCtD
Lamivudine—Confusional state—Bleomycin—skin cancer	0.000256	0.00147	CcSEcCtD
Lamivudine—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000256	0.00146	CcSEcCtD
Lamivudine—ABCG2—Fluoropyrimidine Activity—ERCC2—skin cancer	0.000255	0.00691	CbGpPWpGaD
Lamivudine—Oedema—Bleomycin—skin cancer	0.000254	0.00145	CcSEcCtD
Lamivudine—Anaphylactic shock—Bleomycin—skin cancer	0.000254	0.00145	CcSEcCtD
Lamivudine—Back pain—Temozolomide—skin cancer	0.000254	0.00145	CcSEcCtD
Lamivudine—PCYT2—Metabolism—PLIN2—skin cancer	0.000253	0.00687	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—PLIN2—skin cancer	0.000253	0.00687	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—PLIN2—skin cancer	0.000253	0.00687	CbGpPWpGaD
Lamivudine—Pruritus—Imiquimod—skin cancer	0.000253	0.00145	CcSEcCtD
Lamivudine—Infection—Bleomycin—skin cancer	0.000252	0.00144	CcSEcCtD
Lamivudine—ABCB1—epithelium—skin cancer	0.000251	0.0029	CbGeAlD
Lamivudine—Dysphagia—Docetaxel—skin cancer	0.00025	0.00143	CcSEcCtD
Lamivudine—Nausea—Vemurafenib—skin cancer	0.000249	0.00143	CcSEcCtD
Lamivudine—Thrombocytopenia—Bleomycin—skin cancer	0.000249	0.00142	CcSEcCtD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—PLIN2—skin cancer	0.000249	0.00674	CbGpPWpGaD
Lamivudine—Myalgia—Dactinomycin—skin cancer	0.000247	0.00141	CcSEcCtD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—CDK4—skin cancer	0.000246	0.00667	CbGpPWpGaD
Lamivudine—Tremor—Temozolomide—skin cancer	0.000246	0.00141	CcSEcCtD
Lamivudine—Alopecia—Fluorouracil—skin cancer	0.000245	0.00141	CcSEcCtD
Lamivudine—Diarrhoea—Imiquimod—skin cancer	0.000245	0.0014	CcSEcCtD
Lamivudine—Discomfort—Dactinomycin—skin cancer	0.000244	0.0014	CcSEcCtD
Lamivudine—Ill-defined disorder—Temozolomide—skin cancer	0.000244	0.00139	CcSEcCtD
Lamivudine—Anaemia—Temozolomide—skin cancer	0.000243	0.00139	CcSEcCtD
Lamivudine—Anorexia—Bleomycin—skin cancer	0.000242	0.00139	CcSEcCtD
Lamivudine—Erythema—Fluorouracil—skin cancer	0.000242	0.00138	CcSEcCtD
Lamivudine—Angioedema—Temozolomide—skin cancer	0.00024	0.00137	CcSEcCtD
Lamivudine—Pancytopenia—Docetaxel—skin cancer	0.000238	0.00136	CcSEcCtD
Lamivudine—Hypotension—Bleomycin—skin cancer	0.000237	0.00136	CcSEcCtD
Lamivudine—Oedema—Dactinomycin—skin cancer	0.000237	0.00136	CcSEcCtD
Lamivudine—Malaise—Temozolomide—skin cancer	0.000237	0.00136	CcSEcCtD
Lamivudine—Dizziness—Imiquimod—skin cancer	0.000236	0.00135	CcSEcCtD
Lamivudine—Vertigo—Temozolomide—skin cancer	0.000236	0.00135	CcSEcCtD
Lamivudine—Infection—Dactinomycin—skin cancer	0.000235	0.00135	CcSEcCtD
Lamivudine—Leukopenia—Temozolomide—skin cancer	0.000235	0.00135	CcSEcCtD
Lamivudine—NME1—Posttranslational regulation of adherens junction stability and dissassembly—HRAS—skin cancer	0.000235	0.00637	CbGpPWpGaD
Lamivudine—Neutropenia—Docetaxel—skin cancer	0.000234	0.00134	CcSEcCtD
Lamivudine—Thrombocytopenia—Dactinomycin—skin cancer	0.000232	0.00133	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000231	0.00132	CcSEcCtD
Lamivudine—SLC22A3—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.00023	0.00623	CbGpPWpGaD
Lamivudine—Cough—Temozolomide—skin cancer	0.000229	0.00131	CcSEcCtD
Lamivudine—Paraesthesia—Bleomycin—skin cancer	0.000228	0.00131	CcSEcCtD
Lamivudine—Convulsion—Temozolomide—skin cancer	0.000227	0.0013	CcSEcCtD
Lamivudine—Vomiting—Imiquimod—skin cancer	0.000227	0.0013	CcSEcCtD
Lamivudine—Dyspnoea—Bleomycin—skin cancer	0.000226	0.0013	CcSEcCtD
Lamivudine—Anorexia—Dactinomycin—skin cancer	0.000226	0.00129	CcSEcCtD
Lamivudine—Rash—Imiquimod—skin cancer	0.000225	0.00129	CcSEcCtD
Lamivudine—Dermatitis—Imiquimod—skin cancer	0.000225	0.00129	CcSEcCtD
Lamivudine—Headache—Imiquimod—skin cancer	0.000224	0.00128	CcSEcCtD
Lamivudine—Anaemia—Fluorouracil—skin cancer	0.000224	0.00128	CcSEcCtD
Lamivudine—Arthralgia—Temozolomide—skin cancer	0.000223	0.00128	CcSEcCtD
Lamivudine—Myalgia—Temozolomide—skin cancer	0.000223	0.00128	CcSEcCtD
Lamivudine—Anxiety—Temozolomide—skin cancer	0.000223	0.00128	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000222	0.00127	CcSEcCtD
Lamivudine—ABCG2—lymph node—skin cancer	0.000222	0.00256	CbGeAlD
Lamivudine—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000221	0.00127	CcSEcCtD
Lamivudine—Discomfort—Temozolomide—skin cancer	0.000221	0.00126	CcSEcCtD
Lamivudine—Decreased appetite—Bleomycin—skin cancer	0.000221	0.00126	CcSEcCtD
Lamivudine—Renal failure—Docetaxel—skin cancer	0.00022	0.00126	CcSEcCtD
Lamivudine—Neuropathy peripheral—Docetaxel—skin cancer	0.000219	0.00125	CcSEcCtD
Lamivudine—Dry mouth—Temozolomide—skin cancer	0.000219	0.00125	CcSEcCtD
Lamivudine—ABCB1—mammalian vulva—skin cancer	0.000218	0.00252	CbGeAlD
Lamivudine—Stomatitis—Docetaxel—skin cancer	0.000218	0.00125	CcSEcCtD
Lamivudine—Jaundice—Docetaxel—skin cancer	0.000218	0.00125	CcSEcCtD
Lamivudine—NME2—Validated targets of C-MYC transcriptional activation—TP53—skin cancer	0.000217	0.0059	CbGpPWpGaD
Lamivudine—Pain—Bleomycin—skin cancer	0.000217	0.00124	CcSEcCtD
Lamivudine—Leukopenia—Fluorouracil—skin cancer	0.000216	0.00124	CcSEcCtD
Lamivudine—Confusional state—Temozolomide—skin cancer	0.000216	0.00124	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000216	0.00124	CcSEcCtD
Lamivudine—Oedema—Temozolomide—skin cancer	0.000214	0.00123	CcSEcCtD
Lamivudine—Anaphylactic shock—Temozolomide—skin cancer	0.000214	0.00123	CcSEcCtD
Lamivudine—Infection—Temozolomide—skin cancer	0.000213	0.00122	CcSEcCtD
Lamivudine—Nausea—Imiquimod—skin cancer	0.000212	0.00122	CcSEcCtD
Lamivudine—Hepatobiliary disease—Docetaxel—skin cancer	0.000211	0.00121	CcSEcCtD
Lamivudine—Epistaxis—Docetaxel—skin cancer	0.000211	0.00121	CcSEcCtD
Lamivudine—Nervous system disorder—Temozolomide—skin cancer	0.00021	0.0012	CcSEcCtD
Lamivudine—Thrombocytopenia—Temozolomide—skin cancer	0.00021	0.0012	CcSEcCtD
Lamivudine—Convulsion—Fluorouracil—skin cancer	0.00021	0.0012	CcSEcCtD
Lamivudine—Feeling abnormal—Bleomycin—skin cancer	0.000209	0.0012	CcSEcCtD
Lamivudine—Agranulocytosis—Docetaxel—skin cancer	0.000208	0.00119	CcSEcCtD
Lamivudine—Skin disorder—Temozolomide—skin cancer	0.000208	0.00119	CcSEcCtD
Lamivudine—Hyperhidrosis—Temozolomide—skin cancer	0.000207	0.00119	CcSEcCtD
Lamivudine—PGK1—Metabolism—PLIN2—skin cancer	0.000207	0.0056	CbGpPWpGaD
Lamivudine—Chest pain—Fluorouracil—skin cancer	0.000206	0.00118	CcSEcCtD
Lamivudine—Myalgia—Fluorouracil—skin cancer	0.000206	0.00118	CcSEcCtD
Lamivudine—Decreased appetite—Dactinomycin—skin cancer	0.000206	0.00118	CcSEcCtD
Lamivudine—NT5C—Metabolism—CSPG4—skin cancer	0.000204	0.00554	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—CSPG4—skin cancer	0.000204	0.00554	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—CSPG4—skin cancer	0.000204	0.00554	CbGpPWpGaD
Lamivudine—Fatigue—Dactinomycin—skin cancer	0.000204	0.00117	CcSEcCtD
Lamivudine—Anorexia—Temozolomide—skin cancer	0.000204	0.00117	CcSEcCtD
Lamivudine—Discomfort—Fluorouracil—skin cancer	0.000203	0.00116	CcSEcCtD
Lamivudine—Pain—Dactinomycin—skin cancer	0.000203	0.00116	CcSEcCtD
Lamivudine—Urticaria—Bleomycin—skin cancer	0.000202	0.00116	CcSEcCtD
Lamivudine—Rhinitis—Docetaxel—skin cancer	0.000201	0.00115	CcSEcCtD
Lamivudine—Body temperature increased—Bleomycin—skin cancer	0.000201	0.00115	CcSEcCtD
Lamivudine—Hepatitis—Docetaxel—skin cancer	0.000201	0.00115	CcSEcCtD
Lamivudine—Hypoaesthesia—Docetaxel—skin cancer	0.000199	0.00114	CcSEcCtD
Lamivudine—Confusional state—Fluorouracil—skin cancer	0.000199	0.00114	CcSEcCtD
Lamivudine—Pharyngitis—Docetaxel—skin cancer	0.000199	0.00114	CcSEcCtD
Lamivudine—PGK1—Disease—CSPG4—skin cancer	0.000199	0.00539	CbGpPWpGaD
Lamivudine—Oedema—Fluorouracil—skin cancer	0.000197	0.00113	CcSEcCtD
Lamivudine—Anaphylactic shock—Fluorouracil—skin cancer	0.000197	0.00113	CcSEcCtD
Lamivudine—Connective tissue disorder—Docetaxel—skin cancer	0.000197	0.00113	CcSEcCtD
Lamivudine—Infection—Fluorouracil—skin cancer	0.000196	0.00112	CcSEcCtD
Lamivudine—Feeling abnormal—Dactinomycin—skin cancer	0.000195	0.00112	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000195	0.00112	CcSEcCtD
Lamivudine—Insomnia—Temozolomide—skin cancer	0.000194	0.00111	CcSEcCtD
Lamivudine—Gastrointestinal pain—Dactinomycin—skin cancer	0.000194	0.00111	CcSEcCtD
Lamivudine—ABCB1—lymphoid tissue—skin cancer	0.000194	0.00224	CbGeAlD
Lamivudine—Nervous system disorder—Fluorouracil—skin cancer	0.000194	0.00111	CcSEcCtD
Lamivudine—Thrombocytopenia—Fluorouracil—skin cancer	0.000193	0.00111	CcSEcCtD
Lamivudine—Paraesthesia—Temozolomide—skin cancer	0.000192	0.0011	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—PLIN2—skin cancer	0.000192	0.00521	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	0.000191	0.00519	CbGpPWpGaD
Lamivudine—Dyspnoea—Temozolomide—skin cancer	0.000191	0.00109	CcSEcCtD
Lamivudine—Somnolence—Temozolomide—skin cancer	0.00019	0.00109	CcSEcCtD
Lamivudine—ABCC4—Ectoderm Differentiation—SHH—skin cancer	0.00019	0.00517	CbGpPWpGaD
Lamivudine—Erythema multiforme—Docetaxel—skin cancer	0.00019	0.00109	CcSEcCtD
Lamivudine—Dyspepsia—Temozolomide—skin cancer	0.000189	0.00108	CcSEcCtD
Lamivudine—Anorexia—Fluorouracil—skin cancer	0.000188	0.00108	CcSEcCtD
Lamivudine—Abdominal pain—Dactinomycin—skin cancer	0.000187	0.00107	CcSEcCtD
Lamivudine—Body temperature increased—Dactinomycin—skin cancer	0.000187	0.00107	CcSEcCtD
Lamivudine—Hypersensitivity—Bleomycin—skin cancer	0.000187	0.00107	CcSEcCtD
Lamivudine—ABCB1—female reproductive system—skin cancer	0.000187	0.00216	CbGeAlD
Lamivudine—Decreased appetite—Temozolomide—skin cancer	0.000186	0.00107	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Temozolomide—skin cancer	0.000185	0.00106	CcSEcCtD
Lamivudine—Fatigue—Temozolomide—skin cancer	0.000185	0.00106	CcSEcCtD
Lamivudine—Hypotension—Fluorouracil—skin cancer	0.000184	0.00106	CcSEcCtD
Lamivudine—Pain—Temozolomide—skin cancer	0.000183	0.00105	CcSEcCtD
Lamivudine—Constipation—Temozolomide—skin cancer	0.000183	0.00105	CcSEcCtD
Lamivudine—Asthenia—Bleomycin—skin cancer	0.000182	0.00104	CcSEcCtD
Lamivudine—Immune system disorder—Docetaxel—skin cancer	0.000181	0.00104	CcSEcCtD
Lamivudine—Mediastinal disorder—Docetaxel—skin cancer	0.000181	0.00103	CcSEcCtD
Lamivudine—Chills—Docetaxel—skin cancer	0.00018	0.00103	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.00018	0.00103	CcSEcCtD
Lamivudine—Pruritus—Bleomycin—skin cancer	0.00018	0.00103	CcSEcCtD
Lamivudine—Insomnia—Fluorouracil—skin cancer	0.000179	0.00102	CcSEcCtD
Lamivudine—Paraesthesia—Fluorouracil—skin cancer	0.000177	0.00101	CcSEcCtD
Lamivudine—Alopecia—Docetaxel—skin cancer	0.000177	0.00101	CcSEcCtD
Lamivudine—Feeling abnormal—Temozolomide—skin cancer	0.000177	0.00101	CcSEcCtD
Lamivudine—Dyspnoea—Fluorouracil—skin cancer	0.000176	0.00101	CcSEcCtD
Lamivudine—NME2—Metabolism—PLIN2—skin cancer	0.000176	0.00476	CbGpPWpGaD
Lamivudine—Somnolence—Fluorouracil—skin cancer	0.000175	0.001	CcSEcCtD
Lamivudine—Gastrointestinal pain—Temozolomide—skin cancer	0.000175	0.001	CcSEcCtD
Lamivudine—Erythema—Docetaxel—skin cancer	0.000175	0.001	CcSEcCtD
Lamivudine—Malnutrition—Docetaxel—skin cancer	0.000175	0.001	CcSEcCtD
Lamivudine—Hypersensitivity—Dactinomycin—skin cancer	0.000174	0.000999	CcSEcCtD
Lamivudine—Dyspepsia—Fluorouracil—skin cancer	0.000174	0.000995	CcSEcCtD
Lamivudine—SLC22A6—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000173	0.00469	CbGpPWpGaD
Lamivudine—Decreased appetite—Fluorouracil—skin cancer	0.000172	0.000982	CcSEcCtD
Lamivudine—Dysgeusia—Docetaxel—skin cancer	0.000171	0.000979	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Fluorouracil—skin cancer	0.00017	0.000976	CcSEcCtD
Lamivudine—Urticaria—Temozolomide—skin cancer	0.00017	0.000974	CcSEcCtD
Lamivudine—Asthenia—Dactinomycin—skin cancer	0.00017	0.000973	CcSEcCtD
Lamivudine—Abdominal pain—Temozolomide—skin cancer	0.000169	0.00097	CcSEcCtD
Lamivudine—Body temperature increased—Temozolomide—skin cancer	0.000169	0.00097	CcSEcCtD
Lamivudine—Back pain—Docetaxel—skin cancer	0.000169	0.000967	CcSEcCtD
Lamivudine—Pain—Fluorouracil—skin cancer	0.000169	0.000967	CcSEcCtD
Lamivudine—Muscle spasms—Docetaxel—skin cancer	0.000168	0.000961	CcSEcCtD
Lamivudine—PGK1—Metabolism—CSPG4—skin cancer	0.000167	0.00452	CbGpPWpGaD
Lamivudine—NME1—Validated targets of C-MYC transcriptional activation—TP53—skin cancer	0.000165	0.00447	CbGpPWpGaD
Lamivudine—Feeling abnormal—Fluorouracil—skin cancer	0.000163	0.000931	CcSEcCtD
Lamivudine—Diarrhoea—Dactinomycin—skin cancer	0.000162	0.000928	CcSEcCtD
Lamivudine—Vomiting—Bleomycin—skin cancer	0.000161	0.000925	CcSEcCtD
Lamivudine—Anaemia—Docetaxel—skin cancer	0.000161	0.000924	CcSEcCtD
Lamivudine—Rash—Bleomycin—skin cancer	0.00016	0.000917	CcSEcCtD
Lamivudine—Dermatitis—Bleomycin—skin cancer	0.00016	0.000916	CcSEcCtD
Lamivudine—Hypersensitivity—Temozolomide—skin cancer	0.000158	0.000904	CcSEcCtD
Lamivudine—Urticaria—Fluorouracil—skin cancer	0.000157	0.000898	CcSEcCtD
Lamivudine—Syncope—Docetaxel—skin cancer	0.000157	0.000896	CcSEcCtD
Lamivudine—Leukopenia—Docetaxel—skin cancer	0.000156	0.000895	CcSEcCtD
Lamivudine—ABCB1—head—skin cancer	0.000156	0.0018	CbGeAlD
Lamivudine—Body temperature increased—Fluorouracil—skin cancer	0.000156	0.000893	CcSEcCtD
Lamivudine—PCYT1A—Metabolism—CSPG4—skin cancer	0.000155	0.0042	CbGpPWpGaD
Lamivudine—Asthenia—Temozolomide—skin cancer	0.000154	0.00088	CcSEcCtD
Lamivudine—Loss of consciousness—Docetaxel—skin cancer	0.000153	0.000879	CcSEcCtD
Lamivudine—Cough—Docetaxel—skin cancer	0.000152	0.000872	CcSEcCtD
Lamivudine—Pruritus—Temozolomide—skin cancer	0.000152	0.000868	CcSEcCtD
Lamivudine—Convulsion—Docetaxel—skin cancer	0.000151	0.000866	CcSEcCtD
Lamivudine—Nausea—Bleomycin—skin cancer	0.000151	0.000864	CcSEcCtD
Lamivudine—Vomiting—Dactinomycin—skin cancer	0.000151	0.000862	CcSEcCtD
Lamivudine—Rash—Dactinomycin—skin cancer	0.000149	0.000855	CcSEcCtD
Lamivudine—Chest pain—Docetaxel—skin cancer	0.000149	0.000851	CcSEcCtD
Lamivudine—Arthralgia—Docetaxel—skin cancer	0.000149	0.000851	CcSEcCtD
Lamivudine—Myalgia—Docetaxel—skin cancer	0.000149	0.000851	CcSEcCtD
Lamivudine—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000148	0.000845	CcSEcCtD
Lamivudine—Diarrhoea—Temozolomide—skin cancer	0.000147	0.000839	CcSEcCtD
Lamivudine—Hypersensitivity—Fluorouracil—skin cancer	0.000145	0.000833	CcSEcCtD
Lamivudine—Dry mouth—Docetaxel—skin cancer	0.000145	0.000832	CcSEcCtD
Lamivudine—SLC22A2—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000144	0.00391	CbGpPWpGaD
Lamivudine—Confusional state—Docetaxel—skin cancer	0.000144	0.000823	CcSEcCtD
Lamivudine—Anaphylactic shock—Docetaxel—skin cancer	0.000142	0.000816	CcSEcCtD
Lamivudine—Oedema—Docetaxel—skin cancer	0.000142	0.000816	CcSEcCtD
Lamivudine—Dizziness—Temozolomide—skin cancer	0.000142	0.000811	CcSEcCtD
Lamivudine—NME2—Metabolism—CSPG4—skin cancer	0.000142	0.00384	CbGpPWpGaD
Lamivudine—Infection—Docetaxel—skin cancer	0.000142	0.00081	CcSEcCtD
Lamivudine—Nausea—Dactinomycin—skin cancer	0.000141	0.000806	CcSEcCtD
Lamivudine—Shock—Docetaxel—skin cancer	0.00014	0.000803	CcSEcCtD
Lamivudine—Nervous system disorder—Docetaxel—skin cancer	0.00014	0.0008	CcSEcCtD
Lamivudine—Pruritus—Fluorouracil—skin cancer	0.00014	0.0008	CcSEcCtD
Lamivudine—Thrombocytopenia—Docetaxel—skin cancer	0.000139	0.000799	CcSEcCtD
Lamivudine—NT5C—Metabolism—ENO2—skin cancer	0.000139	0.00377	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—ENO2—skin cancer	0.000139	0.00377	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—ENO2—skin cancer	0.000139	0.00377	CbGpPWpGaD
Lamivudine—Skin disorder—Docetaxel—skin cancer	0.000138	0.000792	CcSEcCtD
Lamivudine—ABCG2—HIF-1-alpha transcription factor network—TERT—skin cancer	0.000137	0.00372	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	0.000137	0.00371	CbGpPWpGaD
Lamivudine—Vomiting—Temozolomide—skin cancer	0.000136	0.00078	CcSEcCtD
Lamivudine—Anorexia—Docetaxel—skin cancer	0.000136	0.000778	CcSEcCtD
Lamivudine—PGK1—Disease—ENO2—skin cancer	0.000135	0.00367	CbGpPWpGaD
Lamivudine—PGK1—Disease—SHH—skin cancer	0.000135	0.00367	CbGpPWpGaD
Lamivudine—Rash—Temozolomide—skin cancer	0.000135	0.000773	CcSEcCtD
Lamivudine—Diarrhoea—Fluorouracil—skin cancer	0.000135	0.000773	CcSEcCtD
Lamivudine—Dermatitis—Temozolomide—skin cancer	0.000135	0.000773	CcSEcCtD
Lamivudine—SLC22A1—SLC-mediated transmembrane transport—SLC12A2—skin cancer	0.000134	0.00364	CbGpPWpGaD
Lamivudine—Headache—Temozolomide—skin cancer	0.000134	0.000768	CcSEcCtD
Lamivudine—NME1—Metabolism—PLIN2—skin cancer	0.000133	0.00361	CbGpPWpGaD
Lamivudine—Hypotension—Docetaxel—skin cancer	0.000133	0.000762	CcSEcCtD
Lamivudine—ABCC3—Fluoropyrimidine Activity—TP53—skin cancer	0.000132	0.00358	CbGpPWpGaD
Lamivudine—Dizziness—Fluorouracil—skin cancer	0.000131	0.000747	CcSEcCtD
Lamivudine—Musculoskeletal discomfort—Docetaxel—skin cancer	0.00013	0.000743	CcSEcCtD
Lamivudine—Insomnia—Docetaxel—skin cancer	0.000129	0.000738	CcSEcCtD
Lamivudine—Paraesthesia—Docetaxel—skin cancer	0.000128	0.000733	CcSEcCtD
Lamivudine—Nausea—Temozolomide—skin cancer	0.000127	0.000729	CcSEcCtD
Lamivudine—Dyspnoea—Docetaxel—skin cancer	0.000127	0.000727	CcSEcCtD
Lamivudine—Somnolence—Docetaxel—skin cancer	0.000127	0.000725	CcSEcCtD
Lamivudine—Vomiting—Fluorouracil—skin cancer	0.000125	0.000719	CcSEcCtD
Lamivudine—Dyspepsia—Docetaxel—skin cancer	0.000125	0.000718	CcSEcCtD
Lamivudine—ABCC1—Arachidonic acid metabolism—PTGS2—skin cancer	0.000125	0.00338	CbGpPWpGaD
Lamivudine—Rash—Fluorouracil—skin cancer	0.000124	0.000713	CcSEcCtD
Lamivudine—Dermatitis—Fluorouracil—skin cancer	0.000124	0.000712	CcSEcCtD
Lamivudine—ABCC4—Fluoropyrimidine Activity—TP53—skin cancer	0.000124	0.00336	CbGpPWpGaD
Lamivudine—Decreased appetite—Docetaxel—skin cancer	0.000124	0.000709	CcSEcCtD
Lamivudine—Headache—Fluorouracil—skin cancer	0.000124	0.000708	CcSEcCtD
Lamivudine—Gastrointestinal disorder—Docetaxel—skin cancer	0.000123	0.000704	CcSEcCtD
Lamivudine—Fatigue—Docetaxel—skin cancer	0.000123	0.000703	CcSEcCtD
Lamivudine—Constipation—Docetaxel—skin cancer	0.000122	0.000698	CcSEcCtD
Lamivudine—Pain—Docetaxel—skin cancer	0.000122	0.000698	CcSEcCtD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	0.000119	0.00323	CbGpPWpGaD
Lamivudine—Feeling abnormal—Docetaxel—skin cancer	0.000117	0.000672	CcSEcCtD
Lamivudine—Nausea—Fluorouracil—skin cancer	0.000117	0.000671	CcSEcCtD
Lamivudine—SLC22A3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000117	0.00317	CbGpPWpGaD
Lamivudine—Gastrointestinal pain—Docetaxel—skin cancer	0.000116	0.000667	CcSEcCtD
Lamivudine—PGK1—Metabolism—ENO2—skin cancer	0.000113	0.00307	CbGpPWpGaD
Lamivudine—Abdominal pain—Docetaxel—skin cancer	0.000113	0.000645	CcSEcCtD
Lamivudine—Body temperature increased—Docetaxel—skin cancer	0.000113	0.000645	CcSEcCtD
Lamivudine—PGK1—Disease—FOXO4—skin cancer	0.00011	0.00299	CbGpPWpGaD
Lamivudine—ABCB1—lymph node—skin cancer	0.000109	0.00126	CbGeAlD
Lamivudine—PCYT2—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	0.000109	0.00295	CbGpPWpGaD
Lamivudine—NME1—Metabolism—CSPG4—skin cancer	0.000107	0.00291	CbGpPWpGaD
Lamivudine—ABCC3—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000107	0.00291	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—ENO2—skin cancer	0.000105	0.00285	CbGpPWpGaD
Lamivudine—Hypersensitivity—Docetaxel—skin cancer	0.000105	0.000601	CcSEcCtD
Lamivudine—DCK—Retinoblastoma (RB) in Cancer—TP53—skin cancer	0.000105	0.00284	CbGpPWpGaD
Lamivudine—Asthenia—Docetaxel—skin cancer	0.000102	0.000585	CcSEcCtD
Lamivudine—ABCC4—Transmembrane transport of small molecules—SLC12A2—skin cancer	0.000101	0.00274	CbGpPWpGaD
Lamivudine—Pruritus—Docetaxel—skin cancer	0.000101	0.000577	CcSEcCtD
Lamivudine—Diarrhoea—Docetaxel—skin cancer	9.75e-05	0.000558	CcSEcCtD
Lamivudine—NME2—Metabolism—ENO2—skin cancer	9.63e-05	0.00261	CbGpPWpGaD
Lamivudine—Dizziness—Docetaxel—skin cancer	9.42e-05	0.000539	CcSEcCtD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PLIN2—skin cancer	9.33e-05	0.00253	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	9.15e-05	0.00248	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PLIN2—skin cancer	9.13e-05	0.00248	CbGpPWpGaD
Lamivudine—ABCG2—Fluoropyrimidine Activity—TP53—skin cancer	9.09e-05	0.00247	CbGpPWpGaD
Lamivudine—Vomiting—Docetaxel—skin cancer	9.06e-05	0.000519	CcSEcCtD
Lamivudine—Rash—Docetaxel—skin cancer	8.98e-05	0.000514	CcSEcCtD
Lamivudine—Dermatitis—Docetaxel—skin cancer	8.97e-05	0.000514	CcSEcCtD
Lamivudine—Headache—Docetaxel—skin cancer	8.92e-05	0.000511	CcSEcCtD
Lamivudine—SLC22A6—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.78e-05	0.00238	CbGpPWpGaD
Lamivudine—ABCC2—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.51e-05	0.00231	CbGpPWpGaD
Lamivudine—Nausea—Docetaxel—skin cancer	8.46e-05	0.000485	CcSEcCtD
Lamivudine—ABCC1—Transmembrane transport of small molecules—SLC12A2—skin cancer	8.41e-05	0.00228	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	8.23e-05	0.00223	CbGpPWpGaD
Lamivudine—NME1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	8.13e-05	0.00221	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—ERCC2—skin cancer	8.07e-05	0.00219	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—ERCC2—skin cancer	8.07e-05	0.00219	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—ERCC2—skin cancer	8.07e-05	0.00219	CbGpPWpGaD
Lamivudine—ABCC1—Defective AMN causes hereditary megaloblastic anemia 1—PTGS2—skin cancer	7.99e-05	0.00217	CbGpPWpGaD
Lamivudine—PGK1—Disease—ERCC2—skin cancer	7.85e-05	0.00213	CbGpPWpGaD
Lamivudine—ABCB1—HIF-1-alpha transcription factor network—TERT—skin cancer	7.42e-05	0.00201	CbGpPWpGaD
Lamivudine—ABCG2—Transmembrane transport of small molecules—SLC12A2—skin cancer	7.4e-05	0.00201	CbGpPWpGaD
Lamivudine—DCK—Metabolism—CSPG4—skin cancer	7.36e-05	0.002	CbGpPWpGaD
Lamivudine—PGK1—Disease—TERT—skin cancer	7.36e-05	0.002	CbGpPWpGaD
Lamivudine—SLC22A2—Transmembrane transport of small molecules—SLC12A2—skin cancer	7.32e-05	0.00199	CbGpPWpGaD
Lamivudine—NME1—Metabolism—ENO2—skin cancer	7.29e-05	0.00198	CbGpPWpGaD
Lamivudine—SLC22A1—Transmembrane transport of small molecules—SLC12A2—skin cancer	6.82e-05	0.00185	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—ERCC2—skin cancer	6.58e-05	0.00178	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—ERCC2—skin cancer	6.11e-05	0.00166	CbGpPWpGaD
Lamivudine—PGK1—Disease—BRAF—skin cancer	5.83e-05	0.00158	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—SHH—skin cancer	5.82e-05	0.00158	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PLIN2—skin cancer	5.77e-05	0.00156	CbGpPWpGaD
Lamivudine—NME2—Metabolism—ERCC2—skin cancer	5.59e-05	0.00152	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—SMO—skin cancer	5.52e-05	0.0015	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PLIN2—skin cancer	5.3e-05	0.00144	CbGpPWpGaD
Lamivudine—DCK—Metabolism—ENO2—skin cancer	5e-05	0.00136	CbGpPWpGaD
Lamivudine—PCYT2—Metabolism—PTGS2—skin cancer	4.84e-05	0.00131	CbGpPWpGaD
Lamivudine—CMPK1—Metabolism—PTGS2—skin cancer	4.84e-05	0.00131	CbGpPWpGaD
Lamivudine—NT5C—Metabolism—PTGS2—skin cancer	4.84e-05	0.00131	CbGpPWpGaD
Lamivudine—PGK1—Disease—PTGS2—skin cancer	4.71e-05	0.00128	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—CSPG4—skin cancer	4.65e-05	0.00126	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—BRAF—skin cancer	4.43e-05	0.0012	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—CSPG4—skin cancer	4.27e-05	0.00116	CbGpPWpGaD
Lamivudine—NME1—Metabolism—ERCC2—skin cancer	4.24e-05	0.00115	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PLIN2—skin cancer	4.15e-05	0.00113	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—BRAF—skin cancer	4.13e-05	0.00112	CbGpPWpGaD
Lamivudine—ABCB1—Transmembrane transport of small molecules—SLC12A2—skin cancer	4e-05	0.00108	CbGpPWpGaD
Lamivudine—ABCC1—Disease—CSPG4—skin cancer	4e-05	0.00108	CbGpPWpGaD
Lamivudine—PGK1—Metabolism—PTGS2—skin cancer	3.94e-05	0.00107	CbGpPWpGaD
Lamivudine—PCYT1A—Metabolism—PTGS2—skin cancer	3.67e-05	0.000994	CbGpPWpGaD
Lamivudine—PGK1—Disease—NRAS—skin cancer	3.66e-05	0.000994	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PLIN2—skin cancer	3.65e-05	0.000991	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PLIN2—skin cancer	3.62e-05	0.000981	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—BRAF—skin cancer	3.39e-05	0.00092	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PLIN2—skin cancer	3.37e-05	0.000914	CbGpPWpGaD
Lamivudine—NME2—Metabolism—PTGS2—skin cancer	3.35e-05	0.000909	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—CSPG4—skin cancer	3.35e-05	0.000908	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—BRAF—skin cancer	3.16e-05	0.000858	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ENO2—skin cancer	3.16e-05	0.000857	CbGpPWpGaD
Lamivudine—PGK1—Disease—KRAS—skin cancer	3.15e-05	0.000855	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—CSPG4—skin cancer	2.95e-05	0.000799	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—CSPG4—skin cancer	2.92e-05	0.000791	CbGpPWpGaD
Lamivudine—DCK—Metabolism—ERCC2—skin cancer	2.91e-05	0.000788	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ENO2—skin cancer	2.9e-05	0.000788	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—CDK4—skin cancer	2.84e-05	0.000769	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—CSPG4—skin cancer	2.72e-05	0.000737	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ENO2—skin cancer	2.72e-05	0.000737	CbGpPWpGaD
Lamivudine—ABCC1—Disease—SHH—skin cancer	2.72e-05	0.000737	CbGpPWpGaD
Lamivudine—PGK1—Disease—HRAS—skin cancer	2.68e-05	0.000727	CbGpPWpGaD
Lamivudine—PGK1—Disease—IL6—skin cancer	2.56e-05	0.000696	CbGpPWpGaD
Lamivudine—NME1—Metabolism—PTGS2—skin cancer	2.54e-05	0.000689	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ENO2—skin cancer	2.28e-05	0.000617	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	2.27e-05	0.000616	CbGpPWpGaD
Lamivudine—ABCC1—Disease—FOXO4—skin cancer	2.21e-05	0.000601	CbGpPWpGaD
Lamivudine—SLC22A2—Transmission across Chemical Synapses—HRAS—skin cancer	2.04e-05	0.000552	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—PTGS2—skin cancer	2.03e-05	0.00055	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ENO2—skin cancer	2e-05	0.000543	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ENO2—skin cancer	1.98e-05	0.000537	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PLIN2—skin cancer	1.98e-05	0.000536	CbGpPWpGaD
Lamivudine—SLC22A1—Transmission across Chemical Synapses—HRAS—skin cancer	1.9e-05	0.000515	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ENO2—skin cancer	1.85e-05	0.000501	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—ERCC2—skin cancer	1.84e-05	0.000498	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—NRAS—skin cancer	1.82e-05	0.000495	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism of lipids and lipoproteins—PTGS2—skin cancer	1.78e-05	0.000483	CbGpPWpGaD
Lamivudine—DCK—Metabolism—PTGS2—skin cancer	1.74e-05	0.000473	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—ERCC2—skin cancer	1.69e-05	0.000458	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—CSPG4—skin cancer	1.59e-05	0.000432	CbGpPWpGaD
Lamivudine—ABCC1—Disease—ERCC2—skin cancer	1.58e-05	0.000428	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—KRAS—skin cancer	1.57e-05	0.000426	CbGpPWpGaD
Lamivudine—SLC22A2—Neuronal System—HRAS—skin cancer	1.56e-05	0.000423	CbGpPWpGaD
Lamivudine—ABCC1—Disease—TERT—skin cancer	1.48e-05	0.000401	CbGpPWpGaD
Lamivudine—SLC22A1—Neuronal System—HRAS—skin cancer	1.45e-05	0.000394	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—TP53—skin cancer	1.4e-05	0.000379	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—skin cancer	1.36e-05	0.000368	CbGpPWpGaD
Lamivudine—ABCC4—Hemostasis—HRAS—skin cancer	1.34e-05	0.000362	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—ERCC2—skin cancer	1.32e-05	0.000359	CbGpPWpGaD
Lamivudine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—skin cancer	1.21e-05	0.000327	CbGpPWpGaD
Lamivudine—ABCC1—Disease—BRAF—skin cancer	1.17e-05	0.000318	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—ERCC2—skin cancer	1.16e-05	0.000315	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—ERCC2—skin cancer	1.15e-05	0.000312	CbGpPWpGaD
Lamivudine—SLC22A3—Metabolism—PTGS2—skin cancer	1.1e-05	0.000298	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—ENO2—skin cancer	1.08e-05	0.000294	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—ERCC2—skin cancer	1.07e-05	0.000291	CbGpPWpGaD
Lamivudine—ABCC3—Metabolism—PTGS2—skin cancer	1.01e-05	0.000274	CbGpPWpGaD
Lamivudine—ABCC1—Disease—PTGS2—skin cancer	9.46e-06	0.000257	CbGpPWpGaD
Lamivudine—ABCC1—Metabolism—PTGS2—skin cancer	7.93e-06	0.000215	CbGpPWpGaD
Lamivudine—ABCC1—Disease—NRAS—skin cancer	7.36e-06	0.0002	CbGpPWpGaD
Lamivudine—ABCG2—Metabolism—PTGS2—skin cancer	6.97e-06	0.000189	CbGpPWpGaD
Lamivudine—SLC22A2—Metabolism—PTGS2—skin cancer	6.9e-06	0.000187	CbGpPWpGaD
Lamivudine—SLC22A1—Metabolism—PTGS2—skin cancer	6.43e-06	0.000174	CbGpPWpGaD
Lamivudine—ABCC1—Disease—KRAS—skin cancer	6.34e-06	0.000172	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—ERCC2—skin cancer	6.29e-06	0.000171	CbGpPWpGaD
Lamivudine—ABCC1—Disease—HRAS—skin cancer	5.39e-06	0.000146	CbGpPWpGaD
Lamivudine—ABCC1—Disease—IL6—skin cancer	5.16e-06	0.00014	CbGpPWpGaD
Lamivudine—ABCB1—Metabolism—PTGS2—skin cancer	3.77e-06	0.000102	CbGpPWpGaD
